The primary known causes of COPD are smoking, occupational exposure to dust and chemicals, and heredity. Some COPD research indicates chronic viral infection as a possible COPD trigger.
In this major COPD breakthrough, researchers have decoded the first part of the molecular strain that links viral infection to COPD.
Research data evidenced rhinovirus, influenza virus, and para influenza virus infection as possible causes of COPD.
Triple therapy, a regimen of a long-acting B-agonist (LABA), an inhaled corticosteroid, and an antimuscarinic agent, COPD symptoms to half, research finds. The study was based on the results of 600 patients with moderate to severe symptoms of COPD.
Scientists at the Johns Hopkins Bloomberg School of Public Health discovered a correlation between a decline in the lung’s antioxidant defense system and the progress of COPD. This discovery was based on the findings that showed the expression NRF2 significantly decreased in smokers with advanced COPD as compared to smokers without COPD.
Roflumilast, a class 4 drug, has been approved by the U.S. Food and Drug Administration to treat COPD. Daily intake of roflumilast helps decrease the frequency of COPD attacks and prevents COPD symptoms from worsening.
For more information on COPD, see below:
Do I Have Bronchitis?
Bronchitis: How Your Diet Plays a Role
© 2017 Newsmax. All rights reserved.